78
Participants
Start Date
May 31, 2011
Primary Completion Date
October 31, 2014
Study Completion Date
October 31, 2014
ibrutinib
ibrutinib is an inhibitor of BTK
New York University, New York
Weill Medical College of Cornell University, New York
Memorial Sloan-Kettering Cancer Center, New York
Long Island Jewish Medical Center, New Hyde Park
University of Rochester School of Medicine and Dentistry, Rochester
The Ohio Sate university, Columbus
University of Wisconsin, Madison
Mayo Clinic, Rochester
University of Nebraska Medical Center, Omaha
The University of Texas MD Anderson Cancer Center, Houston
UCLA Medical Center, Los Angeles
Stanford University School of Medicine, Stanford
Univerity of Washington, Seattle
National Cancer Institute, Bethesda
Hackensack University Medical Center, Hackensack
Lead Sponsor
Pharmacyclics LLC.
INDUSTRY